7.37
0.11 (1.45%)
| Previous Close | 7.26 |
| Open | 7.24 |
| Volume | 946,441 |
| Avg. Volume (3M) | 3,820,804 |
| Market Cap | 1,600,404,352 |
| Price / Earnings (Forward) | 16.00 |
| Price / Sales | 1.71 |
| Price / Book | 0.720 |
| 52 Weeks Range | |
| Earnings Date | 8 Jan 2026 |
| Profit Margin | -53.56% |
| Operating Margin (TTM) | 2.45% |
| Diluted EPS (TTM) | -2.23 |
| Quarterly Revenue Growth (YOY) | -3.40% |
| Total Debt/Equity (MRQ) | 33.61% |
| Current Ratio (MRQ) | 3.91 |
| Operating Cash Flow (TTM) | 68.45 M |
| Levered Free Cash Flow (TTM) | 1.26 M |
| Return on Assets (TTM) | 0.59% |
| Return on Equity (TTM) | -16.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Neogen Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | -0.75 |
|
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 0.38% |
| % Held by Institutions | 128.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Clarkston Capital Partners, Llc | 30 Sep 2025 | 11,693,250 |
| Cibc Bancorp Usa Inc. | 30 Sep 2025 | 5,073,316 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (CJS Securities, 35.78%) | Buy |
| Median | 8.25 (12.02%) | |
| Low | 6.50 (Piper Sandler, -11.75%) | Hold |
| Average | 8.25 (12.02%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 6.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| CJS Securities | 10 Dec 2025 | 10.00 (35.78%) | Buy | 6.98 |
| Piper Sandler | 16 Oct 2025 | 6.50 (-11.74%) | Hold | 5.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Jan 2026 | Announcement | Neogen® Announces Two Senior Leadership Appointments |
| 18 Dec 2025 | Announcement | Neogen Announces Second-Quarter Earnings Release Date |
| 17 Dec 2025 | Announcement | Neogen® To Participate in Upcoming Investor Conferences |
| 30 Oct 2025 | Announcement | Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |